Examining the link between blood microRNAs and Alzheimer's disease risk and severity
Study on the Relationship Between Peripheral Blood miRNA and Risk and Severity of Alzheimer's Disease
This study is trying to see if certain tiny molecules in the blood can help us understand the risk and severity of Alzheimer's disease in both patients and healthy volunteers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 65 Years and up |
| Sex | All |
| Sponsor | Tongji Hospital Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06442852 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between peripheral blood microRNAs and the risk and severity of Alzheimer's Disease (AD). It aims to identify potential biomarkers that could help in understanding the progression of AD and its underlying mechanisms. The study includes both Alzheimer's patients who meet specific diagnostic criteria and healthy volunteers without cognitive impairment. By analyzing blood samples, researchers hope to uncover insights into how microRNAs may influence the disease's development and severity.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with Alzheimer's disease and healthy volunteers without cognitive impairment.
Not a fit: Patients with dementia due to other diseases or those with severe cognitive impairments unrelated to Alzheimer's may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the identification of new biomarkers for early detection and monitoring of Alzheimer's disease.
How similar studies have performed: While the relationship between microRNAs and Alzheimer's disease is being explored, this specific approach is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Alzheimer's disease patients: * Meet the diagnostic criteria of NINCDS-ADRDA for AD * Clinical Dementia Scale (CDR) score ≥0.5 Healthy volunteers: * No complaints or symptoms of cognitive impairment * MMSE score is higher than the threshold value Exclusion Criteria: Alzheimer's disease patients: * Dementia or cognitive impairment due to other diseases * Combined with delirium * A history of drug abuse * Severe deafness, aphasia and other impact scale score Healthy volunteers: * had an organic brain lesion * Suffering from other major physical diseases: such as severe immune diseases
Where this trial is running
Wuhan, Hubei
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China (Recruiting)
Study contacts
- Principal investigator: Kai Zheng — Tongji Hospital
- Study coordinator: Jiajie Chen
- Email: 1005843466@qq.com
- Phone: 0086-15927561646
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.